Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 4
2006 3
2007 1
2008 3
2009 7
2010 7
2011 6
2012 9
2013 12
2014 17
2015 15
2016 32
2017 33
2018 25
2019 24
2020 35
2021 38
2022 31
2023 22
2024 18
2025 26
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Results by year

Filters applied: . Clear all
Page 1
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.
Soo RA, Fernandez-Penas P, Li M, Voon PJ, Tanizaki J, Tseng JS, Tan C, Dong XR, Prabhash K, Kim HR, Hasegawa K, Parkinson N, Kam J, Simoes J, McGeachie M, Lu S, Pavlakis N. Soo RA, et al. Among authors: kim hr. Lung Cancer. 2026 Jun;216:109405. doi: 10.1016/j.lungcan.2026.109405. Epub 2026 Apr 7. Lung Cancer. 2026. PMID: 42048802 Free article. Review.
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC).
Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Goto Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K. Sugawara S, et al. Among authors: kim hr. Future Oncol. 2026 Feb;22(4):399-416. doi: 10.1080/14796694.2026.2617855. Epub 2026 Feb 4. Future Oncol. 2026. PMID: 41640231 Free PMC article.
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.
Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Goto Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K. Lee JS, et al. Among authors: kim hr. Cancer Sci. 2026 Apr;117(4):1124-1135. doi: 10.1111/cas.70330. Epub 2026 Jan 29. Cancer Sci. 2026. PMID: 41611341 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY, Samol J, Runglodvatana Y, Lee KY, Chang GC, Lee CH, Kowalski D, Saw SPL, Huang Y, Ruiter G, Ahn MJ, Yang TY, Yang CT, Sookprasert A, Nakajima EC, Alfon J, McEwen R, Chang YT, Yang JC. Planchard D, et al. Among authors: kim hr. J Thorac Oncol. 2026 May;21(5):103541. doi: 10.1016/j.jtho.2025.12.080. Epub 2025 Dec 23. J Thorac Oncol. 2026. PMID: 41448488 Free article. Clinical Trial.
335 results